ATLANTA, GA — March 20, 2002 — An experimental device that combines resynchronization and cardioverter defibrillation can improve quality of life, functional capacity and exercise tolerance in patients with heart failure.
The results of this double-blind randomized study were reported today during a late-breaking clinical trials session at the American College of Cardiology 51st Annual Scientific Sessions.
The multi-center trial enrolled 362 patients all of whom were implanted with devices. Randomization occurred prior to discharge when devices were set to resynchronization (CRT) treatment mode in 186 patients and to CRT off mode in 176 control patients. The ICD (implantable combination device) function was active in all patients who were followed at one, three and six months. Following the six-month visit, treatment CRT was activated in the control patients.